Beta Bionics, Inc. — Director's Dealing 2026

Jan 6, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Beta Bionics, Inc. (BBNX)
CIK: 0001674632
Period of Report: 2026-01-02

Reporting Person: Feider Stephen (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-02	Common Stock	M	20000	$5.10	Acquired	62614	Direct
2026-01-02	Common Stock	S	20000	$29.5340	Disposed	42614	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-02	Employee Stock Option (right to buy)	$5.10	M	20000	Disposed	2033-09-13	Common Stock (20000)	Direct

Footnotes

F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.

F2: The weighted average sale price for the transaction reported was $29.534002 and the range of prices were between $29.09 and $30.06. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.